Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFO2G5)

• Drug Name: Afabicin Drug Info
• Synonyms: UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-

Indication

Disease Entry	ICD 11	Status	REF
Acute bacterial skin infection	1C41	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 72696796
  CAS Number: CAS 1518800-35-5
  TTD Drug ID: DMFO2G5

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Enoyl ACP reductase (Stap-coc fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFN-1252	DMTFE9Y	Staphylococcus infection	1B5Y	Phase 2	[2]
CG-400549	DMFAKGR	Bacterial infection	1A00-1C4Z	Phase 2	[3]
MUT-056399	DMC3NSK	Methicillin-resistant staphylococci infection	1A00-1A09	Preclinical	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Enoyl ACP reductase (Stap-coc fabI)	TTZBRVL	FABI_STAA8	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
• [3] In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3.
• [4] The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7.